Management of Parasomnias in Lewy Body Dementia

Diagnosis and Characteristics

REM sleep behavior disorder (RBD) is the most common and concerning type of parasomnia in Lewy body dementia (LBD), characterized by complex, often violent motor behaviors associated with dream enactment due to loss of normal muscle atonia during REM sleep, and diagnosis requires polysomnography (PSG) showing increased electromyographic activity during REM sleep (lack of atonia) 1

The American Geriatrics Society recommends melatonin as a first-line treatment for RBD in LBD, with a starting dose of 3 mg at bedtime and titration up to 15 mg as needed, due to its favorable safety profile and minimal drug-drug interactions 1, 2
Clonazepam can be used as a second-line option for RBD in LBD, but with caution due to risks of cognitive impairment, falls, worsening of sleep apnea, and morning sedation, with a starting dose of 0.25-0.5 mg at bedtime, which can be titrated up to 1-2 mg as needed 1, 2, 3
The American Academy of Sleep Medicine strongly recommends against using sleep-promoting medications other than melatonin and clonazepam for RBD in LBD 4
Clonazepam can reduce sleep-related injury rates from 80.8% pre-treatment to 5.6% post-treatment, but up to 58% of patients may experience moderate to severe side effects, leading to discontinuation in some cases 3

Structured physical and social activity during the day, bright light exposure (2500-5000 lux) for 1-2 hours in the morning, reduction in nighttime light and noise, and improved incontinence care can help manage RBD in LBD 1
Safety interventions, such as removing potentially dangerous objects from the bedroom, padding sharp furniture corners, placing soft carpet or rug next to the bed, considering separate sleeping arrangements for patients with severe RBD, and placing a pillow barrier between patient and bed partner, are paramount and should be implemented for all RBD patients regardless of pharmacological treatment 2, 3

Armodafinil may be considered as a treatment option for excessive daytime sleepiness in LBD, although this should be addressed separately from parasomnia treatment, as recommended by the American Academy of Sleep Medicine 5
Melatonin offers several advantages over SSRIs, including demonstrated efficacy in reducing dream enactment behaviors, a safer profile with fewer adverse effects than clonazepam, less impact on cognition, and minimal drug-drug interactions 2

For elderly patients or those with cognitive impairment, melatonin is preferred due to its fewer cognitive side effects 2
For patients with mild cognitive impairment, transdermal rivastigmine may be considered as a treatment option 2
For patients with Parkinson's disease, clonazepam, melatonin, or transdermal rivastigmine may be considered as treatment options 2
For drug-induced RBD, discontinuing the offending medication is recommended if possible, and considering medications with lower risk of RBD exacerbation if antidepressant therapy is required 2, 3
Methylphenidate, a stimulant medication, can potentially disrupt normal sleep architecture and exacerbate REM sleep abnormalities, though specific evidence for RBD exacerbation is more limited than for antidepressants, according to the American Academy of Sleep Medicine 3

Regular assessment of efficacy and side effects is necessary, and monitoring for emergence of neurodegenerative symptoms, as RBD often precedes synucleinopathies, and evaluating for comorbid sleep disorders, particularly sleep apnea, which can be worsened by clonazepam 3
Long-term treatment (≥6 months) with melatonin appears necessary for sustained benefit, and administration at a consistent time each evening (10-11 pm) enhances efficacy 2